LEXICON PHARMACEUTICALS, INC.
LXRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LXRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LXRX
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for cardiometabolic and other diseases, with its approved drug INPEFA (sotagliflozin) and a pivotal Phase 3 trial in hypertrophic cardiomyopathy (HCM).
Key risk: Clinical trial failure risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.02B
Cash Runway
60.4 moLead Asset
inpefa (Approved)
Next Catalyst
Phase3_Topline · Feb 1, 2027Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 clinical trial · 2 catalysts for LEXICON PHARMACEUTICALS, INC..
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for cardiometabolic and other diseases, with its approved drug INPEFA (sotagliflozin) and a pivotal Phase 3 trial in hypertrophic cardiomyopathy (HCM).
- Lexicon is conducting the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin for hypertrophic cardiomyopathy (HCM) [sec_mda · as of 2026-03-05].
- The company has an exclusive license agreement with Novo Nordisk for LX9851, a preclinical obesity candidate, receiving $45M upfront and $20M in development milestones [sec_mda · as of 2026-05-07].
- Lexicon entered into an exclusive license agreement with Viatris for sotagliflozin outside the U.S. and Europe, receiving a $25M upfront payment [sec_mda · as of 2026-05-07].
- As of 2026-06-30, Lexicon reported cash & equivalents of $40.9M, total revenue of $0.7M, and a net loss of -$31.8M [sec].
- The company has a milestone payment obligation of $5M to Bristol-Myers Squibb upon dosing the first patient in a Phase 3 trial of pilavapadin [sec_mda · as of 2026-08-06].
What works
- Lexicon has secured significant non-dilutive funding through licensing deals, including $45M upfront from Novo Nordisk and $25M from Viatris [sec_mda · as of 2026-05-07].
- The company has a late-stage pipeline with a pivotal Phase 3 trial (SONATA-HCM) for sotagliflozin in HCM, a large unmet medical need [sec_mda · as of 2026-03-05].
- INPEFA (sotagliflozin) is already approved and commercialized, providing a revenue base and regulatory experience [sec_mda · as of 2026-03-05].
What to weigh
- Lexicon has minimal revenue ($0.7M as of 2026-06-30) and continues to operate at a net loss (-$31.8M), indicating heavy reliance on external financing [sec].
- The company faces substantial future capital requirements, dependent on clinical trial success, regulatory approvals, and new collaborations [sec_mda · as of 2026-08-06].
- Lexicon has a $5M milestone payment obligation to Bristol-Myers Squibb for pilavapadin, adding to financial commitments [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Lexicon is conducting a pivotal Phase 3 trial for sotagliflozin in HCM.
“We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertrophic cardiomyopathy, or HCM, and are conducting the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication.”
SEC MD&A · March 5, 2026
Lexicon received $45M upfront from Novo Nordisk for LX9851.
“we entered into an exclusive license agreement with Novo Nordisk A/S for the worldwide development, manufacture and commercialization of LX9851, our preclinical drug candidate for obesity and associated cardiometabolic disorders, pursuant to which we received an upfront payment of $45 million in April 2025”
SEC MD&A · May 7, 2026
Lexicon has a $5M milestone payment obligation to BMS for pilavapadin.
“Under our drug discovery alliance with Bristol-Myers Squibb, we will be required to make a milestone payment of $5 million upon dosing of the first patient in a Phase 3 clinical trial of pilavapadin.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2027-02-01 · Phase3_Topline — Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Ef — Topline data from the SONATA-HCM pivotal trial will determine sotagliflozin's efficacy in HCM and potential for regulatory submission.
- 2030-10-07 · Patent_Expiry · INPEFA — Patent/Exclusivity Expiry: INPEFA — Expiration of INPEFA patent/exclusivity could open the door for generic competition, impacting future revenue.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — The SONATA-HCM Phase 3 trial may fail to meet endpoints, jeopardizing sotagliflozin's HCM approval [sec_mda · as of 2026-03-05].
- Capital needs and dilution — With a net loss of -$31.8M and $40.9M cash, Lexicon may need to raise capital, potentially diluting shareholders [sec].
- Regulatory and commercial hurdles — INPEFA faces competition and reimbursement challenges; ex-U.S. commercialization depends on Viatris [sec_mda · as of 2026-05-07].
- Dependence on partnerships — Revenue relies on milestone payments from Novo Nordisk and Viatris; delays or terminations could impact funding [sec_mda · as of 2026-05-07].
What to watch
- Topline results from the SONATA-HCM Phase 3 trial of sotagliflozin in HCM, expected in 2027 [catalyst_timeline].
- Progress of LX9851 through preclinical development and potential IND filing under the Novo Nordisk license [sec_mda · as of 2026-05-07].
- Milestone payments from Bristol-Myers Squibb for pilavapadin Phase 3 initiation [sec_mda · as of 2026-08-06].
- Cash runway updates and any new financing or partnership announcements [sec].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run LEXICON PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LEXICON PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
60.4 months
D/E 0.43 · 0% dilution
Lead: Approved
4 candidates
2 upcoming, next in ~155d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
132
Total value held
$169.1M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 45,056,338 | $70.3M |
| vanguard capital management llc | 19,038,334 | $29.7M |
| millennium management llc | 4,944,731 | $7.7M |
| blackrock, inc. | 3,322,219 | $5.2M |
| jane street group, llc | 3,238,938 | $5.1M |
| geode capital management, llc | 3,169,111 | $4.9M |
| susquehanna international group, llp | 2,766,264 | $4.3M |
| ubs group ag | 2,483,182 | $3.9M |
| marshall wace, llp | 2,376,304 | $3.7M |
| cibc bancorp usa inc. | 1,800,000 | $2.8M |
Showing top 10 of 132 institutional holders of LEXICON PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 10.7%
- Days to cover
- 8.6
- Shares short
- 22,932,295
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LXRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for LEXICON PHARMACEUTICALS, INC.?
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for cardiometabolic and other diseases, with its approved drug INPEFA (sotagliflozin) and a pivotal Phase 3 trial in hypertrophic cardiomyopathy (HCM).
What is LEXICON PHARMACEUTICALS, INC.'s lead drug candidate?
LEXICON PHARMACEUTICALS, INC.'s most advanced tracked candidate is inpefa (Approved) for heart failure, type 2 diabetes mellitus, chronic kidney disease (CKD).
What is LEXICON PHARMACEUTICALS, INC.'s next catalyst?
LEXICON PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Ef" — expected February 1, 2027.
Who is the CEO of LEXICON PHARMACEUTICALS, INC.?
Dr. Michael S. Exton Ph.D. is the chief executive officer of LEXICON PHARMACEUTICALS, INC. (LXRX).
Where is LEXICON PHARMACEUTICALS, INC. headquartered?
LEXICON PHARMACEUTICALS, INC. (LXRX) is headquartered in The Woodlands, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.